Pelthos Therapeutics Inc. (PTHS) is a publicly traded Healthcare sector company. As of May 21, 2026, PTHS trades at $27.45 with a market cap of $90.89M and a P/E ratio of -1.16. PTHS moved -0.52% today. Year to date, PTHS is -12.55%; over the trailing twelve months it is flat. Its 52-week range spans $13.76 to $54.29. Analyst consensus is strong buy with an average price target of $57.71. Rallies surfaces PTHS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who is trading PTHS stock inside the company?
Recent PTHS insider activity includes Malamut Richard sold 310, Malamut Richard sold 280, Friedberg Ezra M sold 293, Friedberg Ezra M sold 265, and Pauls Matthew sold 415. Rallies tracks insider transaction dates, shares, prices, and estimated values.
PTHS Key Metrics
Key financial metrics for PTHS
Metric
Value
Price
$27.45
Market Cap
$90.89M
P/E Ratio
-1.16
EPS
$-23.04
Dividend Yield
0.00%
52-Week High
$54.29
52-Week Low
$13.76
Volume
2
Avg Volume
0
Revenue (TTM)
$16.80M
Net Income
$-43.32M
Gross Margin
76.25%
Recent PTHS Insider Trades
Malamut Richard sold 310 (~$6.36K) on Apr 2, 2026.
Malamut Richard sold 280 (~$5.98K) on Apr 2, 2026.
Friedberg Ezra M sold 293 (~$6.01K) on Apr 2, 2026.
Friedberg Ezra M sold 265 (~$5.66K) on Apr 2, 2026.
Recent PTHS insider activity includes Malamut Richard sold 310, Malamut Richard sold 280, Friedberg Ezra M sold 293, Friedberg Ezra M sold 265, and Pauls Matthew sold 415. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for PTHS?
Yes. Rallies tracks PTHS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is PTHS research on Rallies investment advice?
No. Rallies provides research, data, and educational context for PTHS. It does not provide personalized investment advice.
